Sandoz Group AG (SDZNY)
Market Cap | 19.63B |
Revenue (ttm) | 10.11B |
Net Income (ttm) | -8.00M |
Shares Out | n/a |
EPS (ttm) | -0.02 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | 0.38 (0.86%) |
Ex-Dividend Date | May 3, 2024 |
Volume | 4,292 |
Open | 44.85 |
Previous Close | 44.99 |
Day's Range | 44.65 - 44.85 |
52-Week Range | 27.79 - 46.80 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Mar 5, 2025 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
Full Company ProfileFinancial Performance
In 2023, Sandoz Group AG's revenue was $9.98 billion, an increase of 7.23% compared to the previous year's $9.31 billion. Earnings were $77.00 million, a decrease of -90.92%.
Financial StatementsNews
Agomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of Directors
ANTWERP, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab') today announced the appointment of Colin Bond to the company's Board of Directors as a non-executive Director and Chairman of the A...
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) One of several biosimilar value drivers for Sandoz Sandoz ...
Sandoz reports third-quarter and nine-month 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launches...
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
MEDIA RELEASE First FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic breast cancer Launch expected to be ...
Sandoz Canada achieves carbon neutral certification for its commercial operations
BOUCHERVILLE, Quebec, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada obtained carbon neutral certification from the engineering consulting firm LCL Engineering, Environment & Sustainable Development ...
Sandoz Group: Moving To A 'Hold' After A 50% Move
Sandoz Group's stock has surged nearly 50% since my last article, driven by strong performance in the generics and biosimilars sector. Read more here.
Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™ (aflibercept-abzv) approved to treat neovascular age-related macular degeneration Further enhances leading US ophthalm...
Sandoz Group AG (SDZNY) (Q2 2024) Earnings Call Transcript Highlights: Strong Biosimilars ...
Sandoz Group AG (SDZNY) (Q2 2024) Earnings Call Transcript Highlights: Strong Biosimilars Growth and Raised Sales Guidance
Half Year 2024 Sandoz Group AG Earnings Call Transcript
Half Year 2024 Sandoz Group AG Earnings Call Transcript
Sandoz Group Non-GAAP EPS of $1.12, revenue of $5B
Sandoz Group Non-GAAP EPS of $1.12, revenue of $5B
Sandoz Group AG (SDZNY) Q2 2024 Earnings Call Transcript
Sandoz Group AG (SDZNY) Q2 2024 Earnings Call Transcript
Sandoz Group AG 2024 Q2 - Results - Earnings Call Presentation
Sandoz Group AG 2024 Q2 - Results - Earnings Call Presentation
Won't see major development in weight loss indication drugs in EU or U.S. until 2030, Sandoz CEO says
Richard Saynor, CEO of Sandoz, discusses the firm's half-year results and shares his outlook for innovation in the weight loss drug market.
Generic weight-loss drugs? They’re coming — eventually, executive says
Sandoz, the generics drugmaker spun off from Novartis, is going to get into making cheap versions of the wildly popular GLP-1 class of drugs to treat diabetes and weight loss. But it may take a while.
Sandoz reports second-quarter sales and half-year 2024 results
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net s...
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Launch across Europe, ...
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Pyzchiva® (ustekinumab-ttwe) is appr...
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines ...
Sandoz reports first quarter 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in U...
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
All proposals of Board of Directors approved Gilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for election confirmed Mathai Mammen, Graeme Pitkethly and ...